참고문헌
- Celik AF, Altiparmak MR, Pamuk GE, Pamuk ON, Tabak F. Association of secondary amyloidosis with common variable immune deficiency and tuberculosis. Yonsei Med J 2005;46:847-850. https://doi.org/10.3349/ymj.2005.46.6.847
- Ernandez T, Mayadas TN. Immunoregulatory role of TNF-alpha in inflammatory kidney diseases. Kidney Int 2009;76:262-276. https://doi.org/10.1038/ki.2009.142
- Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Effectiveness of etanercept vs. cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2064-2069. https://doi.org/10.1093/rheumatology/kes190
- Abdallah E, Waked E. Incidence and clinical outcome of renal amyloidosis: a retrospective study. Saudi J Kidney Dis Transpl 2013;24:950-958. https://doi.org/10.4103/1319-2442.118094
- Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic disease. Mod Rheumatol 2014;24:137-143. https://doi.org/10.3109/14397595.2013.854048
피인용 문헌
- Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis vol.40, pp.1, 2016, https://doi.org/10.1007/s00296-019-04363-z
- Secondary Amyloidosis Presenting as Ischemic Proctitis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/6663391